What clinical evidence supports GLP-1 medications for weight loss
Korenberg JR, Chen XN, Schipper R, Sun Z, Gonsky R, Gerwehr S, Carpenter N et al (1994) Down Syndrome Phenotypes: The Consequences of Chromosomal Imbalance
Tirzepatide produced dramatic weight loss, roughly 20% of which was LBM, which is close to the quarter FFM formula
Dermatology trials noted spontaneous erections and increased sexual desire, leading to development of bremelanotide
In animal models of mania, liraglutide augmented the activity of the mood stabilizers sodium valproate 156 and lithium 157
FDA-Approved vs Research Compounds Understanding the distinction between FDA-approved peptides and research-only compounds is essential for evaluating safety: Category Examples Evidence Base Regulation FDA-Approved Semaglutide (Ozempic), Teriparatide (Forteo), Tesamorelin (Egrifta) Phase I-III clinical trials, post-market surveillance Prescription required, manufactured under cGMP Previously Approved Sermorelin (Geref withdrawn 2008) Clinical trial data exists, but product no longer marketed Research use only (currently) Research Only BPC-157, TB-500, Ipamorelin, KPV Preclinical data (varying depth), no completed human trials Sold for laboratory research, not human consumption For the complete list of FDA-approved peptides and their indications, see our FDA Approved Peptides List 2026 guide
